Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.11B | 1.10B | 1.05B | 1.00B | 931.48M | 818.16M |
Gross Profit | 610.61M | 602.29M | 577.16M | 557.00M | 518.67M | 443.57M |
EBITDA | 415.84M | 442.20M | 406.83M | -17.41M | 400.81M | 319.96M |
Net Income | 24.82M | 44.40M | 51.38M | -233.57M | 116.88M | -38.62M |
Balance Sheet | ||||||
Total Assets | 3.10B | 3.07B | 3.13B | 3.12B | 2.79B | 2.76B |
Cash, Cash Equivalents and Short-Term Investments | 304.39M | 277.24M | 296.41M | 395.21M | 106.92M | 102.45M |
Total Debt | 2.35B | 2.35B | 2.33B | 2.03B | 1.83B | 1.91B |
Total Liabilities | 2.68B | 2.67B | 2.69B | 2.77B | 2.20B | 2.31B |
Stockholders Equity | 414.09M | 404.91M | 443.73M | 350.24M | 586.10M | 452.30M |
Cash Flow | ||||||
Free Cash Flow | 75.13M | 45.09M | -362.71M | 95.58M | 179.38M | 67.08M |
Operating Cash Flow | 239.22M | 224.16M | -147.73M | 277.96M | 281.55M | 120.58M |
Investing Cash Flow | -164.02M | -179.00M | -214.91M | -181.90M | -159.83M | -158.69M |
Financing Cash Flow | -15.95M | -50.56M | 265.96M | 197.76M | -117.29M | 73.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $10.91B | 120.75 | 2.67% | 2.61% | 3.31% | -72.63% | |
71 Outperform | $19.03B | 20.43 | 13.65% | 1.80% | 12.58% | 13.00% | |
70 Outperform | $8.25B | 449.94 | -0.92% | ― | -2.16% | -107.31% | |
65 Neutral | $3.44B | 139.84 | 5.88% | ― | 2.78% | -54.72% | |
60 Neutral | HK$17.07B | 6.10 | -7.44% | 2.88% | 11.55% | -28.15% | |
55 Neutral | $17.04B | ― | -23.82% | ― | -3.47% | 25.55% | |
54 Neutral | $9.13B | ― | -36.89% | ― | 11.57% | -315.25% |
On July 23, 2025, Sterigenics U.S., LLC, a subsidiary of Sotera Health Company, agreed to a $34 million settlement to resolve 129 ethylene oxide claims related to its former Willowbrook, Illinois facility. This settlement, which includes claims set for trials in late 2025 and early 2026, is contingent upon several conditions, including full claimant participation and court approval. Sterigenics denies any liability, emphasizing that the settlement is not an admission of fault or safety hazards posed by the facility’s emissions.
The most recent analyst rating on (SHC) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Sotera Health stock, see the SHC Stock Forecast page.
At its 2025 annual meeting on May 21, Sotera Health Company elected three Class II directors for a three-year term, approved executive compensation, and ratified Ernst & Young LLP as its independent auditor for 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (SHC) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Sotera Health stock, see the SHC Stock Forecast page.